Expertise in
22
conditions

Pascal Joly

CHU De Clermont Ferrand
Clermont-ferrand, FR 
Expertise in
22
conditions
CHU De Clermont Ferrand
Clermont-ferrand, FR 
OverviewLocationsClinical Research

Overview

Pascal Joly practices in Clermont-ferrand, France. Mr. Joly is highly rated in 22 conditions, according to our data. His top areas of expertise are Bullous Pemphigoid, Pemphigus Vulgaris, Pemphigus Foliaceus, and Pemphigus.

His clinical research consists of co-authoring 309 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CHU de Clermont Ferrand
Clermont-ferrand, France
Other Locations
CHU Rouen
Rouen, France
Laboratoire De Biochimie Et Biologie Moléculaire Grand Est, Groupement Hospitalier Est, Bron, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Radiation, Biological
Study Drug: Nivolumab
Study Phase: Phase 2
An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris
An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris
Enrollment Status: Completed
Publish Date: February 13, 2023
Intervention Type: Drug
Study Phase: Phase 2
RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)
RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)
Enrollment Status: Completed
Publish Date: May 29, 2018
Intervention Type: Drug
Study Phase: Phase 3
Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face
Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face
Enrollment Status: Completed
Publish Date: May 29, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

309 Total Publications

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.
Journal: JAMA dermatology
Published: March 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Joly's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 58 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile